相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Efficient and relevant stepwise covariate model building for pharmacometrics
Robin J. Svensson et al.
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2022)
Allometric scaling of therapeutic monoclonal antibodies in preclinical and clinical settings
Eva Germovsek et al.
MABS (2021)
Pharmacokinetic Similarity and Comparative Pharmacodynamics, Safety, Efficacy, and Immunogenicity of DRL_RI Versus Reference Rituximab in Biologics-Naive Patients with Moderate-to-Severe Rheumatoid Arthritis: A Double-Blind, Randomized, Three-Arm Study
Vikram Muralidhar Haridas et al.
BIODRUGS (2020)
The regulation and function of CD20: an enigma of B-cell biology and targeted therapy
Gabriela Pavlasova et al.
HAEMATOLOGICA (2020)
Model-Aided Adults-to-Children Pharmacokinetic Extrapolation and Empirical Body Size-Based Dosing Exploration for Therapeutic Monoclonal Antibodies-Is Allometry a Reasonable Choice?
Yan Xu et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2020)
Population Pharmacokinetics and Pharmacodynamics of Bezlotoxumab in Adults with Primary and Recurrent Clostridium difficile Infection
Ka Lai Yee et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
Randomized, Double-Blind, Pharmacokinetic Equivalence Trial Comparing DRL-Rituximab With MabThera in Patients With Diffuse Large B-Cell Lymphoma
Auro Viswabandya et al.
JOURNAL OF GLOBAL ONCOLOGY (2019)
Progression-free survival at 24 months (PFS24) and subsequent outcome for patients with diffuse large B-cell lymphoma (DLBCL) enrolled on randomized clinical trials
M. J. Maurer et al.
ANNALS OF ONCOLOGY (2018)
Comparative assessment of pharmacokinetics, and pharmacodynamics between RTXM83™, a rituximab biosimilar, and rituximab in diffuse large B-cell lymphoma patients: a population PK model approach
Myrna Candelaria et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2018)
An introduction to biosimilar cancer therapeutics: definitions, rationale for development and regulatory requirements
Christian Buske et al.
FUTURE ONCOLOGY (2017)
Improving Access to Cancer Treatments: The Role of Biosimilars
Rakesh Chopra et al.
JOURNAL OF GLOBAL ONCOLOGY (2017)
Population pharmacokinetics of rituximab in patients with diffuse large B-cell lymphoma and association with clinical outcome
Samo Rozman et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2017)
Guidelines for the management of diffuse large B-cell lymphoma
Sridhar Chaganti et al.
BRITISH JOURNAL OF HAEMATOLOGY (2016)
Non-Hodgkin's Lymphomas, Version 4.2014
Andrew D. Zelenetz et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2014)
Simultaneous Exposure-Response Modeling of ACR20, ACR50, and ACR70 Improvement Scores in Rheumatoid Arthritis Patients Treated With Certolizumab Pegol
B. D. Lacroix et al.
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2014)
A mechanism-Based Approach for Absorption Modeling: The Gastro-Intestinal Transit Time (GITT) Model
Emilie Henin et al.
AAPS JOURNAL (2012)
A Guide to Rational Dosing of Monoclonal Antibodies
Shuang Bai et al.
CLINICAL PHARMACOKINETICS (2012)
A Semi-mechanistic Modeling Strategy for Characterization of Regional Absorption Properties and Prospective Prediction of Plasma Concentrations Following Administration of New Modified Release Formulations
Martin Bergstrand et al.
PHARMACEUTICAL RESEARCH (2012)
Pharmacokinetic-Pharmacodynamic Modeling of Severity Levels of Extrapyramidal Side Effects with Markov Elements
V. Pilla Reddy et al.
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2012)
The predictive significance of CD20 expression in B-cell lymphomas
Veronika Kloboves Prevodnik et al.
DIAGNOSTIC PATHOLOGY (2011)
Mechanistic Modeling of a Magnetic Marker Monitoring Study Linking Gastrointestinal Tablet Transit, In Vivo Drug Release, and Pharmacokinetics
M. Bergstrand et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2009)
Model-Based Prediction of Phase III Overall Survival in Colorectal Cancer on the Basis of Phase II Tumor Dynamics
Laurent Claret et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
A decade of rituximab: Improving survival outcomes in non-Hodgkin's lymphoma
Arturo Molina
ANNUAL REVIEW OF MEDICINE (2008)
Bevacizumab Reduces the Growth Rate Constants of Renal Carcinomas: A Novel Algorithm Suggests Early Discontinuation of Bevacizumab Resulted in a Lack of Survival Advantage
Wilfred D. Stein et al.
ONCOLOGIST (2008)
Revised response criteria for malignant lymphoma
Bruce D. Cheson et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma:: a randomised controlled trial by the MabThera International Trial (MInT) Group
Michael Pfreundschuh et al.
LANCET ONCOLOGY (2006)
A quantitative exploration of surface antigen expression in common B-cell malignancies using flow cytometry
SH Olejniczak et al.
IMMUNOLOGICAL INVESTIGATIONS (2006)
Quasi-equilibrium pharmacokinetic model for drugs exhibiting target-mediated drug disposition
DE Mager et al.
PHARMACEUTICAL RESEARCH (2005)
PsN-Toolkit - A collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM
L Lindbom et al.
COMPUTER METHODS AND PROGRAMS IN BIOMEDICINE (2005)
Perls-speaks-NONMEM (PsN) - a Perl module for NONMEM related programming
L Lindbom et al.
COMPUTER METHODS AND PROGRAMS IN BIOMEDICINE (2004)
Rituximab - A review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia
GL Plosker et al.
DRUGS (2003)
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
B Coiffier et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
A pharmacodynamic Markov mixed-effects model for the effect of temazepam on sleep
MO Karlsson et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2000)
分享论文
